LHLouise Tram Henriksen

Louise Tram Henriksen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Louise Tram Henriksen has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Neuropsychological evaluation of children with brain tumors in Denmark, 2010-2020: A nationwide cohort study

    by Barbara Johanne Thomas Nordhjem, Jonathan Kjær Grønbæk, Clara Emilie Bruun, Birthe Lykke Thomsen, Michael Thude Callesen, Louise Tram Henriksen, Kjeld Schmiegelow, René Mathiasen

    Background: Survivors of childhood central nervous system (CNS) tumors are at high risk of neurocognitive impairment, and international guidelines recommend routine neuropsychological evaluation (NE) during follow-up. However, little is known about how consistently these recommendations were implemented in Danish clinical practice. This study examined the occurrence of NE among children diagnosed with CNS tumors in Denmark. Methods: In this nationwide retrospective cohort study, we identified all children aged 0-17 years diagnosed with CNS tumors in Denmark between 2010 and 2020 (n = 446) using the Danish Childhood Cancer Registry. Medical records were reviewed to determine whether patients had received an NE. Time to first evaluation was analyzed using Cox regression to examine associations with age at diagnosis, sex, and treatment center. Results: Overall, 34.3% of patients received at least 1 NE during follow-up. Among patients alive 2 years after diagnosis, 28.8% had received an NE; this proportion increased to 36.4% among patients who were alive 5 years after diagnosis. Among children diagnosed before the age of 7, the likelihood of receiving an NE increased with age at diagnosis. The likelihood of evaluation also differed between treatment centers. Conclusions: Despite international recommendations for routine neuropsychological follow-up, only a minority of children with CNS tumors in Denmark received an NE during the study period. These findings describe neuropsychological follow-up in Denmark from 2010 to 2020, prior to the implementation of more systematic national initiatives. They highlight an unmet need for systematic neuropsychological monitoring in pediatric neuro-oncology survivorship care.

  • Open Access

    Impact of radiation dose on neurocognitive function and quality of life in long-term survivors of childhood brain tumour

    by Laura Toussaint, Anne Sophie Lind Helligsø, Ludvig Paul Muren, Ali Amidi, Rikke Hedegaard Dahlrot, Louise Tram Henriksen, Maja Vestmø Maraldo, Martin Skovmos Nielsen, Anouk Kirsten Trip, Lisa Maria Wu, et al.

    Background and purpose: Children treated with radiotherapy (RT) for a brain tumour often exhibit neurocognitive impairment and report lower quality of life (QoL) later in life. The aim of this nationwide cross-sectional cohort study was to explore the impact of RT dose to brain organs at risk (OARs) on neurocognition and QoL in long-term survivors of childhood brain tumours. Patient/material and methods: A total of 132 survivors of childhood brain tumours, diagnosed from 2001 to 2017 in Denmark, underwent neurocognitive tests and QoL questionnaires at least 5-years post-diagnosis. Neurocognitive assessments were complete and available for 86 patients (61 no-RT/25 RT), and QoL scores for 107 (79 no-RT/28 RT). Mann Whitney U-tests were used to compare scores between no-RT and RT groups. For scores impacted by RT, OAR-specific robust linear regressions were performed to evaluate RT dose effects while adjusting for potential confounders. Results: Clinically significant overall cognitive impairment was observed for 55% of the neurocognitive sub-cohort, with younger age at treatment time as a significant risk factor, while hydrocephalus status had no impact. There were no statistically significant differences on neurocognitive tests between the RT and no-RT group. However, patients treated with RT had significantly lower scores on the physical and social functioning QoL domains, with mean dose to the pituitary gland and left hippocampus, respectively, as significant predictors. Interpretation: This cross-sectional study indicates that RT dose-effects, particularly in the pituitary gland and left hippocampus, might contribute to reduced QoL in survivors of childhood brain tumours.


  • Open Access

    Impact of the COVID-19 pandemic on referral practices for pediatric central nervous system tumors: A Danish National Comparative Cohort Study

    by Kathrine Synne Weile, René Mathiasen, Anne Sophie Lind Helligsoe, Lene Maria Ørts Clemmensen, Henrik Hasle, Louise Tram Henriksen

    Background: Prolonged Diagnostic Interval (DI)s pose a challenge in childhood central nervous system (CNS) tumors. The coronavirus disease 2019 (COVID-19) pandemic altered contact with healthcare. The aim of this study was to describe DIs in children diagnosed with a CNS tumor in Denmark during the first year of the pandemic. Methods: We performed a retrospective questionnaire study, mapping time intervals and symptoms in the diagnostic pathway. We analyzed DIs measured in days and performed descriptive analyses of symptoms and contacts with health care professionals (HCP). Comparison to a pre-COVID cohort was applied. Intervals were presented as total diagnostic interval (TDI; time from symptom onset to diagnosis); Patient Interval (PI; time from symptom onset to first contact to an HCP); and DI (time from first contact to an HCP to diagnosis). Results: We included 25 patients (median age 8.2 years, 56% female). Median TDI: 98 days (IQR 26 210). The DI constituted the majority of TDI (median 70 days). Low-grade tumors displayed longer TDI than high-grade tumors. No significant difference in TDI was found when compared to a pre-COVID cohort (median 98 vs. 106 days). No hesitance to contact a doctor was reported by 88%, but 24% reported delays attributable to the pandemic. Patients reported more symptoms at onset, and the trajectory in the diagnostic pathways changed with fewer patients assessed by their general practitioner than pre-COVID. Conclusions: The DI was unaltered during the COVID-19 pandemic, but changes in trajectory were reported. Results stress the ongoing need for interventions to promote timely diagnosis.

  • Open Access

    Hjernetegn.dk—The Danish Central Nervous System Tumor Awareness Initiative Digital Decision Support Tool: Design and Implementation Report

    by Kathrine Synne Weile, René Mathiasen, Jeanette Falck Winther, Henrik Hasle, Louise Tram Henriksen

    Background: Childhood tumors in the central nervous system (CNS) have longer diagnostic delays than other pediatric tumors. Vague presenting symptoms pose a challenge in the diagnostic process; it has been indicated that patients and parents may be hesitant to seek help, and health care professionals (HCPs) may lack awareness and knowledge about clinical presentation. To raise awareness among HCPs, the Danish CNS tumor awareness initiative hjernetegn.dk was launched. Objective: This study aims to present the learnings from designing and implementing a decision support tool for HCPs to reduce diagnostic delay in childhood CNS tumors. The aims also include decisions regarding strategies for dissemination and use of social media, and an evaluation of the digital impact 6 months after launch. Methods: The phases of developing and implementing the tool include participatory co-creation workshops, designing the website and digital platforms, and implementing a press and media strategy. The digital impact of hjernetegn.dk was evaluated through website analytics and social media engagement. Implementation (Results): hjernetegn.dk was launched in August 2023. The results after 6 months exceeded key performance indicators. The analysis showed a high number of website visitors and engagement, with a plateau reached 3 months after the initial launch. The LinkedIn campaign and Google Search strategy also generated a high number of impressions and clicks. Conclusions: The findings suggest that the initiative has been successfully integrated, raising awareness and providing a valuable tool for HCPs in diagnosing childhood CNS tumors. The study highlights the importance of interdisciplinary collaboration, co-creation, and ongoing community management, as well as broad dissemination strategies when introducing a digital support tool.


  • Open Access

    Hjernetegn.dk—The Danish Central Nervous System Tumor Awareness Initiative Digital Decision Support Tool: Design and Implementation Report (Preprint)

    by Kathrine Synne Weile, René Mathiasen, Jeanette Falck Winther, Henrik Hasle, Louise Tram Henriksen

    BACKGROUND Childhood tumors in the central nervous system (CNS) have longer diagnostic delays than other pediatric tumors. Vague presenting symptoms pose a challenge in the diagnostic process; it has been indicated that patients and parents may be hesitant to seek help, and health care professionals (HCPs) may lack awareness and knowledge about clinical presentation. To raise awareness among HCPs, the Danish CNS tumor awareness initiative hjernetegn.dk was launched. OBJECTIVE This study aims to present the learnings from designing and implementing a decision support tool for HCPs to reduce diagnostic delay in childhood CNS tumors. The aims also include decisions regarding strategies for dissemination and use of social media, and an evaluation of the digital impact 6 months after launch. METHODS The phases of developing and implementing the tool include participatory co-creation workshops, designing the website and digital platforms, and implementing a press and media strategy. The digital impact of hjernetegn.dk was evaluated through website analytics and social media engagement. RESULTS hjernetegn.dk was launched in August 2023. The results after 6 months exceeded key performance indicators. The analysis showed a high number of website visitors and engagement, with a plateau reached 3 months after the initial launch. The LinkedIn campaign and Google Search strategy also generated a high number of impressions and clicks. CONCLUSIONS The findings suggest that the initiative has been successfully integrated, raising awareness and providing a valuable tool for HCPs in diagnosing childhood CNS tumors. The study highlights the importance of interdisciplinary collaboration, co-creation, and ongoing community management, as well as broad dissemination strategies when introducing a digital support tool.

  • Neurocognitive function and health-related quality of life in a nationwide cohort of long-term childhood brain tumor survivors

    by Anne Sophie L Helligsoe, Louise T Henriksen, Line Kenborg, Yasmin Lassen-Ramshad, Lisa M Wu, Jeanette F Winther, Henrik Hasle, Ali Amidi

    Childhood brain tumor survivors are at high risk of late effects, especially neurocognitive impairment. Limited data are available examining neurocognitive function and associations with quality of life (QoL) in childhood brain tumor survivors. Our aim was to examine neurocognitive function in childhood brain tumor survivors, and associations with QoL and symptom burden. Five–year survivors of brain tumors over the age of 15 were identified in the Danish Childhood Cancer Registry (n = 423). Eligible and consenting participants completed neuropsychological tests and questionnaires assessing QoL, insomnia, fatigue, anxiety, and depression. Survivors treated with radiation (n = 59) were statistically compared with survivors not treated with radiation (n = 102). In total, 170 survivors participated (40.2% participation rate). Sixty-six percent of the survivors who completed neurocognitive tests (n = 161) exhibited overall neurocognitive impairment. Survivors treated with radiation, especially whole-brain irradiation, exhibited poorer neurocognitive outcomes than survivors not treated with radiation. Neurocognitive outcomes for survivors treated with surgery were below normative expectations. Furthermore, a number of survivors experienced significant fatigue (40%), anxiety (23%), insomnia (13%), and/or depression (6%). Survivors treated with radiation reported lower quality of life (QoL) and higher symptom burden scores than survivors not treated with radiation; particularly in physical functioning, and social functioning with symptoms of fatigue. Neurocognitive impairment was not associated with QoL or symptom burden. In this study, a majority of the childhood brain tumor survivors experienced neurocognitive impairment, reduced QoL, and high symptom burden. Although not associated with each other, it is apparent that childhood brain tumor survivors experience not only neurocognitive dysfunction but may also experience QoL impairments and significant symptom burden.


  • Open Access

    Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study

    by Lsl Line Stensig Lynggaard, Cecilie Utke Rank, Stefan Nygaard Hansen, Sofie Gottschalk Højfeldt, Louise Tram Henriksen, Kirsten Brunsvig Jarvis, Susanna Ranta, Riitta Niinimäki, Arja Harila-Saari, Benjamin O Wolthers, et al.

    Asparaginase treatment is a mainstay in contemporary treatment of acute lymphoblastic leukemia (ALL), but substantial asparaginase-related toxicity may lead to jeopardized protocol compliance and compromises survival. We investigated the association between risk of asparaginase-associated toxicities (AspTox) and asparaginase enzyme activity (AEA) levels in 1155 children aged 1.0 to 17.9 years, diagnosed with ALL between July 2008 and March 2016, and treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol. Patients with ≥2 blood samples for AEA measurement drawn 14 ± 2 days after asparaginase administration were included (6944 trough values). AEA was measurable (or >0 IU/L) in 955 patients, whereas 200 patients (17.3%) had asparaginase inactivation and few AspTox recorded. A time-dependent multiple Cox model of time to any first asparaginase-associated toxicity adjusted for sex and age was used. For patients with measurable AEA, we found a hazard ratio (HR) of 1.17 per 100 IU/L increase in median AEA (95% confidence interval [CI], 0.98-1.41; P = .09). For pancreatitis, thromboembolism, and osteonecrosis, the HRs were 1.40 (95% CI, 1.12-1.75; P = .002), 0.99 (95% CI, 0.70-1.40; P = .96), and 1.36 (95% CI, 1.04-1.77; P = .02) per 100 IU/L increase in median AEA, respectively. No significant decrease in the risk of leukemic relapse was found: HR 0.88 per 100 IU/L increase in AEA (95% CI, 0.66-1.16; P = .35). In conclusion, these results emphasize that overall AspTox and relapse are not associated with AEA levels, yet the risk of pancreatitis and osteonecrosis increases with increasing AEA levels.


  • Open Access

    Incidence and survival of childhood central nervous system tumors in Denmark, 1997–2019

    by Anne Sophie Lind Helligsoe, Line Kenborg, Louise Tram Henriksen, Aparna Udupi, Henrik Hasle, Jeanette Falck Winther

    Background: Incidence rates in Denmark of central nervous system (CNS) tumors remain among the highest in the world. Survival rates, however, have improved in the past decades in high‐income countries.Methods: We analyzed incidence and survival of childhood CNS tumors in Denmark diagnosed from 1997 to 2019 based on data from the Danish Childhood Cancer Registry and information on histological types, tumor localization, and treatment from medical records.Results: From 1997 to 2019, 949 childrenn = 374, 39.4%) were treated with surgery alone. Overall survival rates 5 and 10 years after diagnosis were 77.6% (95% CI, 74.7–80.2) and 74.7% (95% CI, 71.7–77.5). Five‐year overall survival improved from 73.0% (95% CI, 68.9–76.7) in 1997–2008 to 83.2% (95% CI, 79.2–86.4) in 2009–2019 (p‐value < 0.0001) in children aged 0–4 years (p = 0.0006).Conclusion: Incidence rates are stable but remain among the highest in the world. Despite improved survival rates in recent years in younger children, some subtypes still have a poor prognosis.


  • Genetic predisposition to PEG‐asparaginase hypersensitivity in children treated according to NOPHO ALL2008

    by Sofie G. Højfeldt, Benjamin O. Wolthers, Morten Tulstrup, Jonas Abrahamsson, Ramneek Gupta, Arja Harila‐Saari, Mats Heyman, Louise T. Henriksen, Òlafur G. Jónsson, Päivi M. Lähteenmäki, et al.

    Summary: Asparaginase is essential in childhood acute lymphoblastic leukaemia (ALL) treatment, however hypersensitivity reactions to pegylated asparaginase (PEG‐asparaginase) hampers anti‐neoplastic efficacy. Patients with PEG‐asparaginase hypersensitivity have been shown to possess zero asparaginase enzyme activity. Using this measurement to define the phenotype, we investigated genetic predisposition to PEG‐asparaginase hypersensitivity in a genome‐wide association study (GWAS). From July 2008 to March 2016, 1494 children were treated on the Nordic Society of Paediatric Haematology and Oncology ALL2008 protocol. Cases were defined by clinical hypersensitivity and no enzyme activity, controls had enzyme activity ≥ 100 iu/l and no hypersensitivity symptoms. PEG‐asparaginase hypersensitivity was reported in 13·8% (206/1494) of patients. Fifty‐nine cases and 772 controls fulfilled GWAS inclusion criteria. The CNOT3 variant rs73062673 on 19q13.42, was associated with PEG‐asparaginase allergy (P = 4·68 × 10−8). We further identified two signals on chromosome 6 in relation to HLA‐DQA1 (P = 9·37 × 10−6) and TAP2 (P = 1·59 × 10−5). This study associated variants in CNOT3 and in the human leucocyte antigen (HLA) region with PEG‐asparaginase hypersensitivity, suggesting that not only genetic variations in the HLA region, but also regulation of these genes are of importance in the biology of this toxicity. Furthermore, our study emphasizes the importance of using asparaginase enzyme activity measurements to identify PEG‐asparaginase hypersensitivity.


  • Prolonged first‐line PEG‐asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol—Pharmacokinetics and antibody formation

    by Louise Tram Henriksen, Sofie Gottschalk Højfeldt, Kjeld Schmiegelow, Thomas Leth Frandsen, Peder Skov Wehner, Henrik Schrøder, Birgitte Klug Albertsen, Nordic Society of Pediatric Hematology and Oncology, NOPHO Group

    Background: As pegylated asparaginase is becoming the preferred first‐line asparaginase preparation in the chemotherapy regimens of childhood acute lymphoblastic leukemia (ALL), there is a need to evaluate this treatment.Methods: The aim of this study was to evaluate the pharmacokinetics of prolonged upfront biweekly PEG‐asparaginase (where PEG is polyethylene glycol) treatment by measuring serum l‐asparaginase activity and formation of anti‐PEG‐asparaginase antibodies. A total of 97 evaluable patients (1–17 years), diagnosed with ALL, and treated according to the NOPHO ALL2008 protocol (where NOPHO is Nordic Society of Paediatric Haematology and Oncology) were included. In the NOPHO ALL2008 protocol, patients are randomized to 8 or 15 doses of intramuscular PEG‐asparaginase (Oncaspar®) 1,000 IU/m²/dose, at 2‐week or 6‐week intervals with a total of 30‐week treatment (Clinical trials.gov. no.: NCT00819351).Results: The pharmacological target of treatment (l‐asparaginase activity above 100 IU/l) was reached in 612 of 652 (94%) samples obtained 14 ± 2 days after PEG‐asparaginase administration. Mean l‐asparaginase activity was 338 IU/l. Six patients had l‐asparaginase activity below 50 IU/l in all samples. A total of 25 patients (26%) developed Immunoglobulin G (IgG) anti‐PEG‐asparaginase antibodies, but there was no correlation between anti‐PEG‐asparaginase antibodies and low levels of asparaginase activity.Conclusion: We conclude that prolonged first‐line biweekly PEG‐asparaginase therapy, 1,000 IU/m²/dose was above the pharmacological target in the vast majority of patients. Presence of anti‐PEG‐asparaginase antibodies was not a predictor of l‐asparaginase activity.